MDHearing Volt vs Resound Vivia 9 60S microRIE

The MDHearing Volt is a budget-priced prescription hearing aid released in 2020, earning a B grade with a SoundScore of 3.0/5 in our lab testing. At $397, it sits in the lowest price tier for prescription devices, ranking #34 of 39 in its category. In our testing, the Volt showed a mixed performance profile with one standout strength: feedback handling scored an excellent 5.0/5, which is 0.28 points above the category average. This means users can expect minimal whistling or squealing during typical wear. However, speech performance was limited, with speech in quiet scoring 1.8/5 (1.65 points below average) and speech in noise at 1.0/5 (1.11 points below average). Own voice comfort was mixed at 2.6/5, roughly matching the category average. Music streaming capability was not functional in our testing, scoring 0.0/5—a significant limitation for users who want to stream audio from their phone. This is 2.76 points below the prescription hearing aid category average. The Volt may appeal to budget-conscious consumers who prioritize basic amplification and feedback-free wear over advanced speech enhancement or streaming features. Those seeking stronger speech performance in the same price range may want to consider alternatives like the RxEars Rxi, which scored 4.07/5 in our testing. The Volt's rechargeable battery and behind-the-ear design offer practical convenience, but its core sound performance reflects its entry-level positioning.

The ReSound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In our lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #29 of 39 prescription hearing aids tested. This device shows a mixed performance profile. Its standout strength is own-voice comfort, scoring 3.4/5—a solid result that sits 0.70 points above the category average. Speech clarity in quiet environments also performs at category average with a score of 3.4/5. Feedback handling is strong in absolute terms at 4.2/5, though this falls 0.52 points below the category average, reflecting the high bar set by competing prescription devices. The Vivia 9's most notable weakness is speech understanding in noisy environments, where it scored just 1.1/5—a low result that trails the category average by 0.96 points. Music streaming performance is mixed at 2.6/5, sitting slightly below average. These limitations are worth considering given the premium price positioning. For listeners who prioritize comfortable own-voice perception and primarily encounter quieter listening situations, the Vivia 9 may be suitable. However, those frequently in challenging noise environments should note that several alternatives in this price range—including the Phonak Sphere Infinio and Oticon Intent—deliver stronger overall performance in our testing. Budget-conscious shoppers may also find comparable sound quality at lower price points with options like the Jabra Enhance Pro 20 at Costco.